These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 39401968)

  • 1. Intratumoral STING agonist reverses immune evasion in PD-(L)1-refractory Merkel cell carcinoma: mechanistic insights from detailed biomarker analyses.
    Pulliam T; Jani S; Goff PH; Bhakuni R; Tabachnick-Cherny S; Smythe K; Seaton BW; Tachiki L; Kulikauskas R; Church C; Koelle DM; Nghiem P; Bhatia S
    J Immunother Cancer; 2024 Oct; 12(10):. PubMed ID: 39401968
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MHC class-I downregulation in PD-1/PD-L1 inhibitor refractory Merkel cell carcinoma and its potential reversal by histone deacetylase inhibition: a case series.
    Ugurel S; Spassova I; Wohlfarth J; Drusio C; Cherouny A; Melior A; Sucker A; Zimmer L; Ritter C; Schadendorf D; Becker JC
    Cancer Immunol Immunother; 2019 Jun; 68(6):983-990. PubMed ID: 30993371
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Merkel polyomavirus-specific T cells fluctuate with merkel cell carcinoma burden and express therapeutically targetable PD-1 and Tim-3 exhaustion markers.
    Afanasiev OK; Yelistratova L; Miller N; Nagase K; Paulson K; Iyer JG; Ibrani D; Koelle DM; Nghiem P
    Clin Cancer Res; 2013 Oct; 19(19):5351-60. PubMed ID: 23922299
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Merkel cell polyomavirus-specific immune responses in patients with Merkel cell carcinoma receiving anti-PD-1 therapy.
    Miller NJ; Church CD; Fling SP; Kulikauskas R; Ramchurren N; Shinohara MM; Kluger HM; Bhatia S; Lundgren L; Cheever MA; Topalian SL; Nghiem P
    J Immunother Cancer; 2018 Nov; 6(1):131. PubMed ID: 30482247
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PD-L1 expression in the Merkel cell carcinoma microenvironment: association with inflammation, Merkel cell polyomavirus and overall survival.
    Lipson EJ; Vincent JG; Loyo M; Kagohara LT; Luber BS; Wang H; Xu H; Nayar SK; Wang TS; Sidransky D; Anders RA; Topalian SL; Taube JM
    Cancer Immunol Res; 2013 Jul; 1(1):54-63. PubMed ID: 24416729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PD-1 and PD-L1 in neoplastic cells and the tumor microenvironment of Merkel cell carcinoma.
    Mitteldorf C; Berisha A; Tronnier M; Pfaltz MC; Kempf W
    J Cutan Pathol; 2017 Sep; 44(9):740-746. PubMed ID: 28569410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transcriptional and functional analyses of neoantigen-specific CD4 T cells during a profound response to anti-PD-L1 in metastatic Merkel cell carcinoma.
    Church C; Pulliam T; Longino N; Park SY; Smythe KS; Makarov V; Riaz N; Jing L; Amezquita R; Campbell JS; Gottardo R; Pierce RH; Choi J; Chan TA; Koelle DM; Nghiem P
    J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36252564
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective reactivation of STING signaling to target Merkel cell carcinoma.
    Liu W; Kim GB; Krump NA; Zhou Y; Riley JL; You J
    Proc Natl Acad Sci U S A; 2020 Jun; 117(24):13730-13739. PubMed ID: 32482869
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predominance of Central Memory T Cells with High T-Cell Receptor Repertoire Diversity is Associated with Response to PD-1/PD-L1 Inhibition in Merkel Cell Carcinoma.
    Spassova I; Ugurel S; Terheyden P; Sucker A; Hassel JC; Ritter C; Kubat L; Habermann D; Farahpour F; Saeedghalati M; Peiffer L; Kumar R; Schrama D; Hoffmann D; Schadendorf D; Becker JC
    Clin Cancer Res; 2020 May; 26(9):2257-2267. PubMed ID: 31932494
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insights into anti-tumor immunity
    Jani S; Church CD; Nghiem P
    Front Immunol; 2023; 14():1172913. PubMed ID: 37287968
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and molecular characteristics associated with response to therapeutic PD-1/PD-L1 inhibition in advanced Merkel cell carcinoma.
    Spassova I; Ugurel S; Kubat L; Zimmer L; Terheyden P; Mohr A; Björn Andtback H; Villabona L; Leiter U; Eigentler T; Loquai C; Hassel JC; Gambichler T; Haferkamp S; Mohr P; Pfoehler C; Heinzerling L; Gutzmer R; Utikal JS; Horny K; Schildhaus HU; Habermann D; Hoffmann D; Schadendorf D; Becker JC
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35074902
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biomarker Analyses Investigating Disease Biology and Associations with Outcomes in the JAVELIN Merkel 200 Trial of Avelumab in Metastatic Merkel Cell Carcinoma.
    D'Angelo SP; Lebbé C; Nghiem P; Brohl AS; Mrowiec T; Leslie T; Georges S; Güzel G; Shah P
    Clin Cancer Res; 2024 Oct; 30(19):4352-4362. PubMed ID: 39047170
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Merkel cell polyomavirus-specific CD8⁺ and CD4⁺ T-cell responses identified in Merkel cell carcinomas and blood.
    Iyer JG; Afanasiev OK; McClurkan C; Paulson K; Nagase K; Jing L; Marshak JO; Dong L; Carter J; Lai I; Farrar E; Byrd D; Galloway D; Yee C; Koelle DM; Nghiem P
    Clin Cancer Res; 2011 Nov; 17(21):6671-80. PubMed ID: 21908576
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial.
    D'Angelo SP; Bhatia S; Brohl AS; Hamid O; Mehnert JM; Terheyden P; Shih KC; Brownell I; Lebbé C; Lewis KD; Linette GP; Milella M; Georges S; Shah P; Ellers-Lenz B; Bajars M; Güzel G; Nghiem PT
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32414862
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regression of metastatic Merkel cell carcinoma following transfer of polyomavirus-specific T cells and therapies capable of re-inducing HLA class-I.
    Chapuis AG; Afanasiev OK; Iyer JG; Paulson KG; Parvathaneni U; Hwang JH; Lai I; Roberts IM; Sloan HL; Bhatia S; Shibuya KC; Gooley T; Desmarais C; Koelle DM; Yee C; Nghiem P
    Cancer Immunol Res; 2014 Jan; 2(1):27-36. PubMed ID: 24432305
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quality Is King: Fundamental Insights into Tumor Antigenicity from Virus-Associated Merkel Cell Carcinoma.
    Lahman MC; Paulson KG; Nghiem PT; Chapuis AG
    J Invest Dermatol; 2021 Aug; 141(8):1897-1905. PubMed ID: 33863500
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rescue therapy for patients with anti-PD-1-refractory Merkel cell carcinoma: a multicenter, retrospective case series.
    LoPiccolo J; Schollenberger MD; Dakhil S; Rosner S; Ali O; Sharfman WH; Silk AW; Bhatia S; Lipson EJ
    J Immunother Cancer; 2019 Jul; 7(1):170. PubMed ID: 31287031
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pembrolizumab and other immune checkpoint inhibitors in locally advanced or metastatic Merkel Cell Carcinoma: safety and efficacy.
    Marchand A; Kervarrec T; Bhatia S; Samimi M
    Expert Rev Anticancer Ther; 2020 Dec; 20(12):1093-1106. PubMed ID: 33044876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Genomic Landscape of Merkel Cell Carcinoma and Clinicogenomic Biomarkers of Response to Immune Checkpoint Inhibitor Therapy.
    Knepper TC; Montesion M; Russell JS; Sokol ES; Frampton GM; Miller VA; Albacker LA; McLeod HL; Eroglu Z; Khushalani NI; Sondak VK; Messina JL; Schell MJ; DeCaprio JA; Tsai KY; Brohl AS
    Clin Cancer Res; 2019 Oct; 25(19):5961-5971. PubMed ID: 31399473
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic Role of Tumoral PD-L1 and IDO1 Expression, and Intratumoral CD8+ and FoxP3+ Lymphocyte Infiltrates in 132 Primary Cutaneous Merkel Cell Carcinomas.
    Donizy P; Wu CL; Kopczynski J; Pieniazek M; Biecek P; Ryś J; Hoang MP
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34071045
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.